Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Elevated intratumoral immune inflammation prior to treatment is typically associated with better outcomes in hot tumors treated with immune checkpoint inhibitors (ICIs). However, we observed a paradox in pMMR/MSS locally advanced rectal cancer (LARC) patients, where a subset with elevated baseline immune inflammation exhibited worse outcomes after combined radiotherapy and ICI treatment compared with patients with minimal immune inflammation.
Abstract Background: Postoperative recurrence remains a major cause of treatment failure and death in patients with locally advanced rectal cancer (LARC), despite advances in neoadjuvant chemoradiotherapy (NCRT) and radical surgery. This study evaluated the prognostic value of initial recurrence patterns on post-recurrence survival (PRS) and examined clinicopathological factors associated with recurrence-free survival (RFS).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
